Analytical Methods for the Determination of Atypical Antipsychotic Drugs - An Update

Abstract

Atypical antipsychotics have gained incredible attention over the last decade and are widely prescribed for short-term and chronic treatment of various psychopathological diseases, including schizophrenia, mania, delirium, bipolar disorder, depression, autism spectrum disorder, and affective disorders. Due to their better clinical profile and therapeutic benefits, atypical antipsychotics have become a better choice for psychopathological treatment and management. However, their usage is associated with peripheral side effects and metabolic diseases impacting the quality of life of patients. In the sight of these circumstances, strategic development of analytical methods to isolate atypical antipsychotics from a variety of formulations and biological samples and identify and quantify them with great sensitivity and accuracy is of great importance in clinical and forensic settings. In the present review, we have summarized and discussed various analytical methods reported in the literature over the last decade in various formulations and biological samples, highlighting analytical trends to the analysts in the field of atypical antipsychotics.

QbD-Driven Development and Validation of a Bioanalytical LC–MS Method for Quantification of Paliperidone in Human Plasma

“…This structured approach has gained widespread acceptance in recent years for its ability to yield bioanalytical methods with enhanced performance characteristics, representing a significant leap forward in analytical science (Chiarentin et al, 2023;Özcan et al, 2023) Recognizing the potential for QbD to revolutionize bioanalytical method development, this research article embarks on a journey to establish a bioanalytical LC-MS technique for Paliperidone quantification in human plasma, meticulously designed and executed in accordance with QbD principles. To maximize analyte recovery from the complex biological matrix and ensure advanced method performance, we take a systematic analytical approach that includes three crucial phases: (1) factor screening to recognize Critical Method Parameters (CMPs); (2) optimization of chromatographic circumstances using a Box-Behnken design; and (3) finetuning of the bioanalytical liquid-liquid extraction progression via a D-optimal design (Suvarna and Raut, 2023;Sathyanarayanan and Somashekara, 2022).…”